Clinical trial NCT00569153: Safety Study of TAK-700 in Subjects With Prostate Cancer.
Official title: A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Prostatic Neoplasms
Keywords: Androgen-independent prostate cancer, metastatic
Lead sponsor: Millennium Pharmaceuticals, Inc.
Sponsor class: INDUSTRY
First posted: 2007-12-06
Enrollment: 123
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.


Eligibility criteria: Inclusion Criteria:

* Subject is male and at least 18 years of age.
* Subject has histologically- or cytologically-confirmed prostate adenocarcinoma with metastatic, progressive disease while on androgen deprivation therapy.
* Subject has radiograph-documented (computed tomography, magnetic resonance imaging or x-ray) metastatic disease.
* Subject has undergone orchiectomy or is expected to continue receiving luteinizing hormone-releasing hormone analogue therapy, and has a testosterone level of \<50 ng/dL at screening.
* Subject has discontinued all antiandrogen therapy (within 30 days for flutamide and within 6 weeks for all others) prior to their first dose of study drug.
* Subject has a prostate-specific antigen level ≥5 ng/mL.
* Subject meets all screening laboratory values as specified in the protocol.
* Subject has a screening ejection fraction that is above the lower limit of the institutional normal range.
* Subject has ECOG performance status of 0 to 2.
* Subject has normal or, in the opinion of the investigator, clinically insignificant, physical examination findings, ECG and chest x-ray results.
* Subjects, even if surgically sterilized (ie, status postvasectomy), who: agree to practice effective barrier contraception during the entire study treatment period and for 4 months after the last dose of study drug, or agree to completely abstain from heterosexual intercourse.

Exclusion Criteria:

* Subject has known hypersensitivity to TAK-700 or related compounds.
* Subject has received prior therapy with aminoglutethimide or ketoconazole within 30 days prior to the first dose of study drug.
* Subject has received prior chemotherapy for prostate cancer.
* Subject has received any investigational compound within 30 days prior to first dose of study drug.
* Subject has received prior herbal product known to decrease prostate-specific antigen levels (eg, Saw Palmetto, PC-SPES) within 30 days prior to the first dose of study drug.
* Subject has received radiation therapy for prostate cancer within 30 days prior to first dose of study drug.
* Chronic therapy with oral or other systemically administered corticosteroids, such as prednisone, within 30 days prior to Screening. Chronic therapy is defined as the use of corticosteroids for more than 7 days within a 30-day period.
* Subject has current spinal cord compression, current bilateral hydronephrosis, or current bladder neck outlet obstruction.
* Subject has a history of adrenal insufficiency.
* Subject has a history of myocardial infarction, ischaemic symptomatic heart disease, cardiac arrhythmias or thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 12 months prior to first dose of study drug.
* Subject has any symptoms which the investigator deems related to prostate cancer, i.e., bone pain, pelvic pain.
* Subject has a history of congestive heart failure (New York Heart Association Class II or greater.
* Subject has history of another malignancy other than basal cell carcinoma or state 1 squamous cell carcinoma of the skin, within the last 5 years.
* Subject has uncontrolled hypertension.
* Subject is known to have HIV infection, chronic Hepatitis B or C or any other serious medical condition or psychiatric illness that might affect life expectancy or make it difficult to successfully manage and follow the subject according to protocol.
* Subject is unable to understand verbal or written English or any other language for which a certified translation of the institutional review board (IRB)-approved informed consent has been provided.
* Subject is unwilling or unable to comply with the protocol or cooperate fully with the investigator and site personnel.

Primary outcomes:
measure: Safety and tolerability of TAK-700 by evaluating adverse events, vital signs, physical examination findings, concomitant medications and laboratory tests.
timeFrame: Cycle 1: Weeks 1, 2, 3 and 4, then every 4 weeks thereafter.
Secondary outcomes:
measure: Efficacy and pharmacokinetics (PSA response and/or objective disease response)
timeFrame: Cycle 1: Weeks 1, 2, 3 and 4, then every 4 weeks thereafter.
Other outcomes:
Locations:
city: Beverly Hills
country: United States
facility: USC Westside Prostate Cancer Center
state: California
city: Los Angeles
country: United States
facility: University of Southern California
state: California
city: Los Angeles
country: United States
facility: The Angeles Clinic and Research Institute
state: California
city: Los Angeles
country: United States
facility: USC Norris Comprehensive Cancer Center
state: California
city: Aventura
country: United States
facility: South Florida Medical Research
state: Florida
city: Fort Myers
country: United States
facility: Florida Cancer Specialists
state: Florida
city: Chicago
country: United States
facility: Northwestern University Medical Center
state: Illinois
city: Chicago
country: United States
facility: University of Chicago
state: Illinois
city: Chicago
country: United States
facility: University of Chicago Comprehensive Cancer Center
state: Illinois
city: Chicago
country: United States
facility: University of Chicago Pharmacy
state: Illinois
city: Evanston
country: United States
facility: Evanston Hospital
state: Illinois
city: Evanston
country: United States
facility: Kellogg Pharmacy - Evanston Hospital
state: Illinois
city: Evanston
country: United States
facility: NorthShore University HealthSystem
state: Illinois
city: Glenview
country: United States
facility: Kellogg Cancer Care Center
state: Illinois
city: East Syracuse
country: United States
facility: Hematology/Oncology Associates of Central New York
state: New York
city: Canton
country: United States
facility: Gabrail Cancer Center
state: Ohio
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
city: Cleveland
country: United States
facility: Taussig Cancer Institute
state: Ohio
city: Nashville
country: United States
facility: Tennessee Oncology
state: Tennessee
Study officials:
affiliation: Millennium Pharmaceuticals, Inc.
name: Medical Monitor
role: STUDY_DIRECTOR
References: